Sutro Biopharma (STRO)
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its prop...
- Open
- 20.830
- High
- 21.120
- Low
- 19.545
- Prev. Close
- 21.040
- Volume
- 123.26K
- Turnover
- 2.50M
- Avg Price
- 20.277
- Bid/Ask Ratio
- 55.73%
- Amplitude
- 7.49%
- 52wk High
- 43.850
- Volume Ratio
- 0.51
- Turnover Ratio
- 0.81%
Sutro Biopharma Analyst Rating
View moreForecast & Rating
Aug 16, 2026Price forecast
$47.23130.62%
Forecast & RatingStrong buy
14analysts
- Strong buy71.43%
- Buy21.43%
- Hold0.00%
- Sell0.00%
- Strong sell7.14%
News
- Weekly Review · 2 days ago, 12:44 AM
Weekly Recap | Sutro Biopharma +2.73%, consensus target well above spot
- benzinga_article · Aug 12 at 01:04 PM
Why is Sutro Biopharma Stock Falling On Wednesday?
- Tip Ranks · Aug 12 at 12:15 PM
Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged
- benzinga_article · Aug 12 at 12:05 PM
12 Industrials Stocks Moving In Wednesday's Intraday Session
- benzinga_article · Aug 12 at 09:19 AM
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
- Earnings Watch · Aug 12 at 06:21 AM
Sutro Biopharma | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.839 M
